MARINUS PHARMACEUTICALS Reports Q2 Earnings Results for FY2023

August 13, 2023

🌥️Earnings Overview

On August 10 2023, MARINUS PHARMACEUTICALS ($NASDAQ:MRNS) reported its earnings for Q2 of FY2023, for the period ending June 30 2023. The total revenue for the quarter was 6.1 million USD, significantly higher than the 1.8 million reported in the same period of the previous year. However, the net income for the quarter was -31.9 million USD, a decrease from the -39.4 million reported in the same quarter of last year.

Market Price

The stock opened at $8.7 and closed at $7.9, a drop of 9.1% from its last closing price of 8.7. This marked a sharp decline in stock price, which had been steadily increasing since the start of the financial year. The company attributed this to increased demand for their products and services worldwide. MARINUS PHARMACEUTICALS is continuing to invest in research and development to bring new drugs and treatments to the market. They hope these investments will help to increase their revenues and profits in the coming quarters.

Additionally, they are seeking to enter new markets and expand their offerings in existing ones. Overall, it appears that MARINUS PHARMACEUTICALS has had a successful quarter despite the drop in stock price. They are continuing to make strategic investments that will benefit the company in the long run. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Marinus Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    25.96 -27.69 -106.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Marinus Pharmaceuticals. More…

    Operations Investing Financing
    -117.39 59.2 93.65
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Marinus Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    201.2 143.86 1.13
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Marinus Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.0% -43.0%
    FCF Margin ROE ROA
    -457.4% -9.8% -3.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    We at GoodWhale recently conducted an analysis of MARINUS PHARMACEUTICALS‘s wellbeing. According to our Risk Rating, MARINUS PHARMACEUTICALS is a medium risk investment in terms of financial and business aspects. We have detected four risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. All registered users are able to view our analysis and uncover the risk warnings. We highly recommend any potential investor to check out our report and draw their own conclusions. With GoodWhale, investors can rest assured that all necessary analyses have been thoroughly conducted and presented in a clear and comprehensive way. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of innovative therapeutics to treat life-threatening, rare neurological disorders. Marinus Pharmaceuticals Inc’s lead drug candidate, ganaxolone, is a novel allosteric modulator of GABAA that is being developed in oral and intravenous formulations. The company’s product pipeline includes two additional drug candidates: IV Ganaxolone for the treatment of status epilepticus, a life-threatening neurological condition; and Caplyta, an oral formulation of clozapine for the treatment of schizophrenia.

    Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for the treatment of serious and rare diseases.

    Sio Gene Therapies Inc is a clinical-stage biotechnology company, which engages in the development and commercialization of gene therapies for the treatment of patients with rare genetic diseases. Its product candidates include Valrox, which is in Phase III clinical trials for the treatment of hemophilia A; and Zinc Finger Transcription Factor 6, which is in Phase I/II clinical trials for the treatment of mucopolysaccharidosis type VI.

    Targovax ASA is a clinical-stage immuno-oncology company developing next-generation immunotherapies to target hard-to-treat solid tumors. The company’s lead product candidate, TG01, is a vaccine targeting the epithelial cell adhesion molecule (EpCAM) expressed on the surface of various epithelial cancers. Targovax ASA’s product pipeline also includes TG02, a vaccine targeting the Wilms tumor 1 (WT1) protein, and TG03, an oncolytic virus.

    – Kiniksa Pharmaceuticals Ltd ($NASDAQ:KNSA)

    Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidate, mavrilimumab, is a monoclonal antibody that inhibits the pro-inflammatory cytokine GM-CSF. Kiniksa Pharmaceuticals Ltd has a market cap of 921.88M as of 2022, a Return on Equity of -41.09%. The company’s focus on autoimmune and inflammatory diseases gives it a strong potential market in the future, however, its current ROE indicates that it is not yet profitable.

    – Sio Gene Therapies Inc ($NASDAQ:SIOX)

    Sio Gene Therapies Inc is a clinical stage gene therapy company. Its main focus is on developing treatments for genetic diseases. The company’s most advanced product is SG-T001, which is in clinical trials for the treatment of X-linked severe combined immunodeficiency (SCID-X1). SG-T001 uses a lentiviral vector to deliver a functional copy of the IL2RG gene to patients’ cells. This product has shown promise in early clinical trials, with patients showing improvements in immune function and reduced virus levels.

    The company has a market cap of 22.44M as of 2022. This is relatively small compared to other companies in the same industry. However, the company’s return on equity is -76.05%. This is due to the fact that the company is still in the early stages of development and has not yet commercialized any products. Despite this, the company’s products show promise and it is worth watching in the future.

    – Targovax ASA ($LTS:0RIS)

    Targovax ASA is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer. The company has a market cap of 206.57M as of 2022 and a Return on Equity of -17.64%. The company’s immunotherapy products are based on its proprietary platform, which includes a range of technologies that are designed to stimulate the body’s immune system to fight cancer cells. Targovax’s products are in various stages of development, with some currently in clinical trials. The company’s most advanced product, TG01, is in Phase III clinical trials for the treatment of ovarian cancer.


    Investors in MARINUS PHARMACEUTICALS should take note of the company’s Q2 FY2023 earnings results, released on August 10 2023. Total revenue for the quarter saw a marked increase from the same period of the previous year, coming in at USD 6.1 million compared to 1.8 million.

    However, net income was -31.9 million, down from -39.4 million in the same quarter of last year. While the significant improvement in revenue could potentially lead to future profitability, the current negative net income figures remain concerning for investors. As a result, the stock price dropped on the same day.

    Recent Posts

    Leave a Comment